Medicina clinica (English ed.)最新文献_第8页

Knowledge about the chain of survival after out-of-hospital cardiac arrest among the citizens of a Spanish region 西班牙某地区居民对院外心脏骤停后存活链的认识

Medicina clinica (English ed.) Pub Date : 2024-09-11 DOI: 10.1016/j.medcle.2024.04.012

Jose Manuel Rabanal Llevot , Francisco Ramos Goicoechea , Juan Carlos Díaz de Téran , Juan Fernando Bermejo Zubelzu

引用次数: 0

Groove pancreatitis: Case report 槽沟胰腺炎病例报告

Medicina clinica (English ed.) Pub Date : 2024-09-11 DOI: 10.1016/j.medcle.2024.03.021

Antonio Bustos-Merlo, Antonio Rosales-Castillo, Pedro Alberto Alarcón-Blanco

引用次数: 0

Eosinophilic granulomatosis with polyangiitis: A rare case of central airway stenosis with normal eosinophil levels 嗜酸性粒细胞肉芽肿伴多血管炎：一例嗜酸性粒细胞水平正常的罕见中央气道狭窄病例

Medicina clinica (English ed.) Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.03.015

Long-zhao Li , Kai Sun , Hong-wu Wang

引用次数: 0

Personalized dosage of Givosiran in acute intermittent porphyria 治疗急性间歇性卟啉症的吉沃西兰个性化剂量

Medicina clinica (English ed.) Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.03.016

Manuel Garrido Montes, Roberto Pertusa Mataix, Jose Salvador Garcia Morillo

引用次数: 0

Marine–Lenhart syndrome as a cause of thyrotoxicosis: A case report Marine-Lenhart综合征是甲状腺毒症的病因之一：病例报告

Medicina clinica (English ed.) Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.02.017

Rosanna del Carmen Zambrano-Infantino, Noelia Álvarez-Mena, Francisco Sebastián-Palacid

引用次数: 0

Medicina clinica (English ed.) Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.03.017

Pablo Martínez Calabuig , Jorge Juan Fragío Gil , Roxana González Mazarío , Fernando López Gutiérrez , Javier Loricera García , Ricardo Blanco Alonso , Cristina Campos Fernández

{"title":"IgG4-related disease: Effectiveness evaluation through Umehara–Okazaki 2011 and ACR/EULAR 2019 diagnostic criteria","authors":"Pablo Martínez Calabuig , Jorge Juan Fragío Gil , Roxana González Mazarío , Fernando López Gutiérrez , Javier Loricera García , Ricardo Blanco Alonso , Cristina Campos Fernández","doi":"10.1016/j.medcle.2024.03.017","DOIUrl":"10.1016/j.medcle.2024.03.017","url":null,"abstract":"<div><h3>Background</h3><p>IgG4-related disease (IgG4-RD) is a rare, systemic immune-mediated fibro-inflammatory condition with an unclear etiology and pathophysiology, potentially affecting multiple organs. It presents with common clinical, radiological, and serological characteristics. This study aims to compare the latest two IgG4-RD classification and diagnostic criteria: Umehara–Okazaki 2011 and ACR/EULAR 2019.</p></div><div><h3>Material and methods</h3><p>In a retrospective cross-sectional study conducted across two centers from January 2010 to July 2023, we included patients suspected of having IgG4-RD from various hospital departments. Patients finally diagnosed with other pathologies were excluded. The remaining suspected IgG4-RD cases were evaluated using both Umehara–Okazaki 2011 and ACR/EULAR 2019 criteria.</p></div><div><h3>Results</h3><p>Out of 34 patients with a clinical diagnosis of IgG4-RD, the Umehara–Okazaki 2011 classified 20 patients: 5 as definitive, 7 as probable, and 8 as possible cases. Applying the ACR/EULAR 2019 criteria to the same cohort resulted in the diagnosis of 9 patients. Notably, retroperitoneal fibrosis and aortitis were the most prevalent form of presentation, accounting for 25% and 22.2% of cases classified under the 2011 and 2019 criteria, respectively.</p></div><div><h3>Discussion</h3><p>The more recent and stringent ACR/EULAR 2019 criteria focus on histopathology, various forms of presentation, and analytical data, allow for a more accurate classification of patients.</p></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 5","pages":"Pages 217-223"},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between adipophilin expression and risk of dyslipidaemia in patients with granuloma annulare 环状肉芽肿患者脂肪蛋白表达与血脂异常风险之间的关系

Medicina clinica (English ed.) Pub Date : 2024-09-10 DOI: 10.1016/j.medcle.2024.01.041

Javier Antoñanzas , Jorge María Núñez-Córdoba , Rafael Salido-Vallejo , Laura Álvarez-Gigli , Ramón Robledano , Agustín España

{"title":"Association between adipophilin expression and risk of dyslipidaemia in patients with granuloma annulare","authors":"Javier Antoñanzas , Jorge María Núñez-Córdoba , Rafael Salido-Vallejo , Laura Álvarez-Gigli , Ramón Robledano , Agustín España","doi":"10.1016/j.medcle.2024.01.041","DOIUrl":"10.1016/j.medcle.2024.01.041","url":null,"abstract":"<div><h3>Background</h3><p>An association between granuloma annulare (GA) and dyslipidaemia has been reported. Adipophilin expression may play a plausible role as a cutaneous biomarker for dyslipidaemia in patients with GA; however, this potential link remains to be explored.</p></div><div><h3>Methods</h3><p>Patients with GA were identified at our hospital between January 1, 1990, and December 31, 2021, with a thorough review of their clinical and histological characteristics. Adipophilin staining was assessed in biopsies of GA lesions.</p></div><div><h3>Results</h3><p>A total of 107 patients with GA were included. The prevalence of dyslipidaemia in patients with positive adipophilin staining was clearly higher than in those with negative labelling (62.3% vs 13.3%). Relative to the dyslipidaemia risk for patients with negative adipophilin expression, the odds for patients with positive adipophilin expression were increased 10-fold (OR: 10.8; <em>p</em>-value<.01). We identified 23 incident cases of dyslipidaemia over a median follow-up period of 91 months among 54 patients with no history of dyslipidaemia. The patients with positive adipophilin expression showed a higher risk of developing dyslipidaemia (HR: 8.9; <em>p</em>-value<.01).</p></div><div><h3>Conclusions</h3><p>Patients with positive adipophilin staining in their GA biopsies were found to be associated with a higher risk for both baseline and incident dyslipidaemia.</p></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 5","pages":"Pages 232-237"},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recommendations update for the diagnosis and treatment of transthyretin variant amyloidosis (ATTRv) 转甲状腺素变异性淀粉样变性（ATTRv）诊断和治疗建议更新

Medicina clinica (English ed.) Pub Date : 2024-09-06 DOI: 10.1016/j.medcle.2024.04.011

Juan González-Moreno , Lucía Galán Dávila , Esther Gonzalez-Lopez , Isabel Conceiçao

引用次数: 0

Diffuse idiopathic pulmonary neuroendocrine cell hiperplasia: a rare cause of lung nodules 弥漫性特发性肺神经内分泌细胞疱疹：肺结节的罕见病因

Medicina clinica (English ed.) Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2024.03.020

Antonio Rosales-Castillo , Antonio Bustos-Merlo , Bélgica Márquez-Lobo

引用次数: 0

Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients 替沙吉单抗/西格维单抗在降低免疫力低下患者 SARS-CoV-2 感染率、住院率和死亡率方面的效果

Medicina clinica (English ed.) Pub Date : 2024-09-04 DOI: 10.1016/j.medcle.2024.03.018

Marc Marti-Pastor , Ricardo Bou-Monterde , Lucia Ciancotti-Oliver , Marta Alcover-Pons , Aurora Amorós Cantero , Raquel Sánchez-Lopezosa , Neus Montañana-Rosell

{"title":"Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients","authors":"Marc Marti-Pastor , Ricardo Bou-Monterde , Lucia Ciancotti-Oliver , Marta Alcover-Pons , Aurora Amorós Cantero , Raquel Sánchez-Lopezosa , Neus Montañana-Rosell","doi":"10.1016/j.medcle.2024.03.018","DOIUrl":"10.1016/j.medcle.2024.03.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Inmunocompromised people have higher SARS-CoV-2 morbi-mortality and they are subsidiary to receive pre-exposure prophylaxis. The objective of this study is to evaluate the effectiveness of tixagevimab/cilgavimab (Evusheld) in preventing SARS-CoV-2 infections, hospitalizations and mortality in immunocompromised patients.</div></div><div><h3>Materials and methods</h3><div>119 immunocompromised people ≥18 years old eligible of receiving Evusheld were followed for 6 months. People with previous SARS-CoV-2 infection or incomplete vaccination regimen were exluded. A total of 19 people who received Evusheld were matched by propensity score, using a 1:1 ratio, with another 19 people who did not receive Evusheld.</div><div>Sociodemographic, related to SARS-CoV-2 risk factors and related to immunosuppression variables were included. The dependent variables were infection, hospitalization, and mortality related to SARS-CoV-2.</div><div>Statistical analyzes were performed using SPSS Statistics 19.0, STATA 11.0, and the R statistical package.</div></div><div><h3>Results</h3><div>In total, 4 people in the Evusheld group and 11 in the control group had SARS-CoV-2 infection, showing an incidence rate of 3.87 and 13.62 per 100 person-months, respectively. The HR (Hazard Ratio) was 0.29 (95% CI = 0.09−0.90) for SARS-CoV-2 infection, 0.37 (0.07−1.92) for SARS-CoV-2 hospitalization and, 0.23 (0.03−2.09) for SARS-CoV-2 mortality in the Evusheld group compared to control group.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that Evusheld reduces the SARS-CoV-2 infections.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 6","pages":"Pages 275-280"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0